Skoči na glavni sadržaj
Veterinary Medicines

Kaltetan forte, 458.4 mg/ml + 125 mg/ml + 20 mg/ml solution for infusion for horses, cattle and pigs

Authorised
  • CALCIUM GLUCONATE FOR INJECTION
  • Magnesium chloride hexahydrate
  • Sodium glycerophosphate pentahydrate

Identifikacija proizvoda

Naziv VMP-a:
Kaltetan forte, 458.4 mg/ml + 125 mg/ml + 20 mg/ml solution for infusion for horses, cattle and pigs
Kaltetan forte, 458,4 mg/ml + 125 mg/ml + 20 mg/ml, infuzinis tirpalas arkliams, galvijams ir kiaulėms
Djelatna tvar:
Način primjene:
  • Intravenski

Pojedinosti o proizvodu

Djelatna tvar i jačina:
  • Dostupno samo u English
    458.40
    miligram
    /
    1.00
    mililitar
  • Dostupno samo u English
    125.00
    miligram
    /
    1.00
    mililitar
  • Dostupno samo u English
    20.00
    miligram
    /
    1.00
    mililitar
Farmaceutski oblik:
  • Otopina za infuziju
Withdrawal period by route of administration:
  • Intravenous use
    • Horse
      • Milk
        5
        week
    • Cattle
      • Meat and offal
        5
        week
    • Pig
      • Meat and offal
        5
        week
Kod anatomsko-terapijsko-kemijske klasifikacije (ATKvet kȏd):
  • QA12AX
Status odobrenja:
  • Važeće
Authorised in:
  • Lithuania
Available in:
  • Lithuania
Opis paketa:

Dodatne informacije

Entitlement type:
Nositelj odobrenja za stavljanje u promet:
  • Vet-Agro Multi-Trade Company Sp. z o.o.
Marketing authorisation date:
Mjesta proizvodnje za izdavanje serije:
  • Multi-Trade Company "Vet-Agro" Sp. z o.o.
Odgovorno tijelo:
  • State Food And Veterinary Service
Broj autorizacije:
  • LT/2/22/2697/001
Datum promjene statusa odobrenja:
Broj postupka:
  • PL/V/0110/002

Dokumenti

RV2697.pdf

Lithuanian (PDF)
Objavljeno na: 25/07/2022
Preuzimanje datoteka
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."